N‐Acetylprocainamide Kinetics During Intravenous Infusions and Subsequent Oral Doses in Patients with Coronary Artery Disease and Ventricular Arrhythmias
Why the study?
What are the pharmacokinetic properties of N-acetylprocainamide during intravenous and oral administration in patients with coronary artery disease and ventricular arrhythmias?
Population
5 male patients, mean age 62, with coronary artery disease and ventricular arrhythmias.
Design
Case_series
Follow-up
19-48 hours (IV) plus subsequent oral dosing period
Authors
Discussion
Loading...
Member takes
Implication
May guide initial NAPA dosing in CAD with arrhythmias; leaves open validation in larger cohorts.
Structured PICO
What are the pharmacokinetic properties of N-acetylprocainamide during intravenous and oral administration in patients with coronary artery disease and ventricular arrhythmias?
P
Population
5 male patients, mean age 62, with coronary artery disease and ventricular arrhythmias.
I
Intervention
N-acetylprocainamide (NAPA) loading infusions of 0.22-0.45 mg/kg/min, prolonged (19-48 hrs) intravenous infusions 2.5-5.2 mg/min, and subsequent oral doses 1.5-3 g every 8 hrs.
O
Outcome
Pharmacokinetics of N-acetylprocainamide (NAPA) including initial distribution volume, steady-state distribution volume, distributional clearance, absorption rate constant, and fraction of dose reaching systemic circulation.surrogate
N-acetylprocainamide kinetics in patients with CAD and ventricular arrhythmias generally follow a two-compartment model with first-order elimination, with complete systemic absorption of oral doses.
Cite This Study
Ludden et al. (1985) studied this question.